Cannabinoids and Epilepsy

Neurotherapeutics

Volumn 12, Issue 4, 2015, Pages 747-768

  Rosenberg, Evan C ^a   Tsien, Richard W ^a   Whalley, Benjamin J ^b   Devinsky, Orrin ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

cannabidiol; cannabinoids; cannabis; Epilepsy; seizures; THC

Indexed keywords

CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABIS; DRONABINOL; ENDOCANNABINOID; ANTICONVULSIVE AGENT;

ANTICONVULSANT ACTIVITY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG INTERACTION; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; HUMAN; LEGAL ASPECT; MEDICAL ETHICS; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; OPEN STUDY; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; TREATMENT RESISTANT EPILEPSY; ANIMAL;

ANIMALS; ANTICONVULSANTS; CANNABINOIDS; EPILEPSY; HUMANS;

EID: 84973890794     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-015-0375-5     Document Type: Review

References (338)

1. Fisher RS, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005;46:470-472.
2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319.
3. Kwan P, Brodie MJ. Refractory epilepsy: a progressive, intractable but preventable condition? Seizure 2002;11:77-84.
4. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med 2011; 365:919-926.
5. Nilsson L, et al. Risk factors for sudden unexpected death in epilepsy: a case–control study. Lancet 1999;353:888-893.
6. Walczak TS, et al. Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. Neurology 2001;56:519-525.
7. Devinsky O. Patients with refractory seizures. N Engl J Med 1999;340:1565-1570.
8. Jacoby A, Baker GA. Quality-of-life trajectories in epilepsy: a review of the literature. Epilepsy Behav 2008;12:557-571.
9. Rogawski MA. The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs. Epilepsia 2013;54(Suppl. 2):33-40.
10. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000;38:191-204.
11. Devinsky O, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791-802.
12. Koppel BS, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82:1556-63.
13. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2014; 3:CD009270.
14. Abel EL. Marihuana: the first twelve thousand years. Plenum Press, New York, 1980.
15. Russo EB, et al. Phytochemical and genetic analyses of ancient cannabis from Central Asia. J Exp Bot 2008;59:4171-4182.
16. Lozano I. The therapeutic use of Cannabis sativa L. in Arabic medicine. J Cannabis Ther 2001;1:63-70.
17. Szaflarski JP, Bebin EM. Cannabis, cannabidiol, and epilepsy—from receptors to clinical response. Epilepsy Behav 2014;41:277-282.
18. O’Shaughnessy WB. On the preparations of the Indian hemp, or Gunjah. Prov Med J Retrosp Med Sci 1843;5:363-369.
19. Reynolds JR. Epilepsy: its symptoms, treatment, and relation to other chronic convulsive diseases. J. Churchill (Ed.) London, 1861.
20. Gowers W. Epilepsy and other chronic convulsive disorders. Churchill (Ed.) London, 1881.
21. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-1647.
22. Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 1971;9:217-224.
23. Adams R, Pease DC, Clark JH. Isolation of cannabinol, cannabidiol, and quebrachitrol from red oil of Minnesota wild hemp. J Am Chem Soc 1940;62: 2194-2196.
24. Michoulam R, Shvo Y., Hashish, I. The structure of cannabidiol. Tetrahedron 1963; 19:2073-2078.
25. Matsuda LA, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.
26. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-65.
27. Llano I, et al. Synaptic- and agonist-induced excitatory currents of Purkinje cells in rat cerebellar slices. J Physiol 1991;434:183-213.
28. A responses in hippocampal pyramidal cells. J Neurosci 1992;12:4122-4132.
29. Kreitzer AC, Regehr WG. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 2001;29:717-727.
30. Kreitzer AC, Regehr WG. Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J Neurosci 2001;21:RC174.
31. Wilson RI, Kunos G, Nicoll RA. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 2001;31:453-462.
32. Devane WA, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949.
33. Mechoulam R, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90.
34. Sugiura T, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215:89-97.
35. Alger BE. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 2002;68:247-286.
36. Brown SP, Brenowitz SD, Regehr WG. Brief presynaptic bursts evoke synapse-specific retrograde inhibition mediated by endogenous cannabinoids. Nat Neurosci 2003;6:1048-1057.
37. Maejima T, Ohno-Shosaku T, Kano M. Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. Neurosci Res 2001;40:205-210.
38. Melis M, et al. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci 2004;24:10707-10715.
39. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008;14:923-930.
40. Di Marzo V, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994;372:686-691.
41. Di Marzo V, Deutsch DG. Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol Dis 1998;5:386-404.
42. Di Marzo V, et al. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998;21:521-528.
43. Sugiura T, et al. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids 2002;66:173-192.
44. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997;388:773-778.
45. Pertwee RG. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs 2000;9:1553-1571.
46. Pi-Sunyer F, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial. JAMA 2006;295:761-775.
47. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev 2007:CD005353.
48. Glass M,. Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 1997;17:5327-5333.
49. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 1992;89:3825-3829.
50. Caulfield MP, Brown DA. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 1992;106:231-232.
51. Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 1997;78:43-50.
52. Szabo GG, et al. Presynaptic calcium channel inhibition underlies CB(1) cannabinoid receptor-mediated suppression of GABA release. J Neurosci 2014;34:7958-7963.
53. Deadwyler SA, et al. Cannabinoids modulate potassium current in cultured hippocampal neurons. Receptors Channels 1993;1:121-134.
54. Deadwyler SA, et al. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J Pharmacol Exp Ther 1995;273:734-743.
55. Hampson RE, et al. Role of cyclic AMP dependent protein kinase in cannabinoid receptor modulation of potassium "A-current" in cultured rat hippocampal neurons. Life Sci 1995;56:2081-2088.
56. Mu J, et al. Protein kinase-dependent phosphorylation and cannabinoid receptor modulation of potassium A current (IA) in cultured rat hippocampal neurons. Pflugers Arch 2000;439:541-546.
57. Henry DJ, Chavkin C. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci Lett 1995;186:91-94.
58. Mackie K, et al. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995;15:6552-6561.
59. McAllister SD, et al. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. J Pharmacol Exp Ther 1999;291:618-626.
60. Photowala H, et al. G protein betagamma-subunits activated by serotonin mediate presynaptic inhibition by regulating vesicle fusion properties. Proc Natl Acad Sci U S A 2006;103:4281-4286.
61. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001;22:565-572.
62. Chevaleyre V, Takahashi KA, Castillo PE. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 2006;29:37-76.
63. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003;4:873-884.
64. Katona I, et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 1999; 19:4544-4558.
65. Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999;11: 4213-4225.
66. Dudok B, et al. Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling. Nat Neurosci 2015;18:75-86.
67. Kawamura Y, et al. The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 2006;26:2991-3001.
68. Katona I, et al. Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 2006;26:5628-5637.
69. Lafourcade M, et al. Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS One 2007;2:e709.
70. Wittmann G, et al. Distribution of type 1 cannabinoid receptor (CB1)-immunoreactive axons in the mouse hypothalamus. J Comp Neurol 2007;503:270-279.
71. Robbe D, et al. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci 2001;21:109-116.
72. Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005;78:539-548.
73. Joy JE. Marijuana and medicine: assessing the science base. National Academics Press, Washington, DC 1999.
74. Huestis MA, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001;58:322-328.
75. Lichtman AH, Martin BR. Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology (Berl) 1996;126: 125-131.
76. Mallet PE, Beninger RJ. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide. Psychopharmacology (Berl) 1998;140:11-19.
77. Varvel SA, et al. Differential effects of delta 9-THC on spatial reference and working memory in mice. Psychopharmacology (Berl) 2001;157:142-150.
78. Da S, Takahashi RN. SR 141716A prevents delta 9-tetrahydrocannabinol-induced spatial learning deficit in a Morris-type water maze in mice. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:321-325.
79. Pagotto U, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27:73-100.
80. Abood ME, et al. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 2001;309:197-201.
81. van der Stelt M, et al. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 2001;21:6475-6479.
82. El-Remessy AB, et al. Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am J Pathol 2003;163:1997-2008.
83. Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 2002;8:58-61.
84. Gilbert GL, et al. Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res 2007;1128:61-69.
85. Nagayama T, et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999;19:2987-2995.
86. Zani A, et al. Delta9-tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors. Br J Pharmacol 2007;152:1301-1311.
87. Hampson AJ, et al. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 1998;95:8268-8273.
88. Molina-Holgado F, Lledo A, Guaza C. Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 1997;8:1929-1933.
89. Molina-Holgado F, et al. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J Neurosci Res 2002;67:829-836.
90. Shohami E, et al. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 1997;72:169-177.
91. Puffenbarger RA, Boothe AC, Cabral GA. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000;29:58-69.
92. Cabral GA, Harmon KN, Carlisle SJ. Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. Adv Exp Med Biol 2001;493:207-214.
93. Ehrhart J, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2005;2:29.
94. Klein TW, et al. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000;225:1-8.
95. Molina-Holgado F, et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 2003;23:6470-6474.
96. Benito C, et al. Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol 2008;153:277-285.
97. De Petrocellis L, et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 2008;325:1007-1015.
98. De Petrocellis L, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163:1479-1494.
99. Qin N, et al. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 2008;28:6231-6238.
100. Vezzani A, et al. The role of inflammation in epilepsy. Nat Rev Neurol 2011;7:31-40.
101. Walker L, Sills GJ. Inflammation and epilepsy: the foundations for a new therapeutic approach in epilepsy? Epilepsy Curr 2012;12:8-12.
102. Devinsky O, et al. Glia and epilepsy: excitability and inflammation. Trends Neurosci 2013;36:174-184.
103. Thomas BF, et al. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 1998;285:285-292.
104. Bisogno T, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845-852.
105. Pertwee RG. GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 2007;152:984-986.
106. Jones NA, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 2010;332:569-577.
107. Russo EB, et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005;30:1037-1043.
108. Ahrens J, et al. The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-Beta glycine receptor function. Pharmacology 2009;83:217-222.
109. Ross HR, Napier I, Connor M. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem 2008;283: 16124-16134.
110. Drysdale AJ, et al. Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells. Neuropharmacology 2006;50:621-631.
111. Ryan D, et al. Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci 2009;29:2053-2063.
112. Rimmerman N, et al. The non-psychoactive plant cannabinoid, cannabidiol affects cholesterol metabolism-related genes in microglial cells. Cell Mol Neurobiol 2011; 31:921-930.
113. Ross RA. The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 2009;30: 156-163.
114. Ryberg E, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152:1092-1101.
115. Lauckner JE, et al. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 2008;105:2699-2704.
116. Oka S, et al. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 2007;362:928-934.
117. Sylantyev S, et al. Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci U S A 2013;110:5193-5198.
118. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A 2006;103:7895-7900.
119. Pandolfo P, et al. Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum. Eur J Pharmacol 2011;655:38-45.
120. Ferre S, et al. Adenosine-cannabinoid receptor interactions. Implications for striatal function. Br J Pharmacol 2010;160:443-453.
121. De Petrocellis L, Di Marzo V. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol 2010;5:103-121.
122. Booz GW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med 2011;51:1054-1061.
123. Hampson AJ, et al. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci 2000;899:274-282.
124. Liou GI, et al. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Invest Ophthalmol Vis Sci 2008;49:5526-5531.
125. Hayakawa K, et al. Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. J Neurochem 2007;102:1488-1496.
126. Hayakawa K, et al. Therapeutic time window of cannabidiol treatment on delayed ischemic damage via high-mobility group box1-inhibiting mechanism. Biol Pharm Bull 2009;32:1538-1544.
127. Iuvone T, et al. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 2004;89:134-141.
128. Esposito G, et al. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 2006;399:91-95.
129. Esposito G, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 2007;151:1272-1279.
130. Pietr M, et al. Differential changes in GPR55 during microglial cell activation. FEBS Lett 2009;583:2071-2076.
131. Staton PC, et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008;139: 225-236.
132. Ben-Shabat S, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 1998;353: 23-31.
133. Wagner H, Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine 2009;16:97-110.
134. Mechoulam R, Ben-Shabat S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Nat Prod Rep 1999;16:131-143.
135. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011;163:1344-1364.
136. Karniol IG, Carlini EA. Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol. Psychopharmacologia 1973;33:53-70.
137. Englund A, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2013;27:19-27.
138. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006;66:234-246.
139. Schubart CD, et al. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 2011;130:216-221.
140. Hemaiswarya S, Kruthiventi AK, Doble M. Synergism between natural products and antibiotics against infectious diseases. Phytomedicine 2008;15:639-652.
141. Tallarida RJ. Quantitative methods for assessing drug synergism. Genes Cancer 2011; 2:1003-1008.
142. Hill AJ, et al. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther 2012;133:79-97.
143. Raol YH, Brooks-Kayal AR. Experimental models of seizures and epilepsies. Prog Mol Biol Transl Sci 2012;105:57-82.
144. Loscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011;20:359-368.
145. Simonato M, et al. The challenge and promise of anti-epileptic therapy development in animal models. Lancet Neurol 2014;13:949-960.
146. Marsicano G, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003;302:84-88.
147. Wallace MJ, et al. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 2003;307: 129-137.
148. Karanian DA, et al. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther 2007;322: 1059-1066.
149. Karanian DA, et al. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci 2005;25:7813-7820.
150. Naidoo V, et al. Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase—dual targets of the endocannabinoid system to protect against seizure pathology. Neurotherapeutics 2012;9:801-813.
151. Deshpande LS, et al. Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur J Pharmacol 2007;558:52-59.
152. Monory K, et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006;51:455-466.
153. Guggenhuber S, et al. AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neurons of the hippocampus protects against seizure-induced excitoxicity. PLoS One 2010;5:e15707.
154. Alger BE. Seizing an opportunity for the endocannabinoid system. Epilepsy Curr 2014; 14:272-276.
155. Falenski KW, et al. Status epilepticus causes a long-lasting redistribution of hippocampal cannabinoid type 1 receptor expression and function in the rat pilocarpine model of acquired epilepsy. Neuroscience 2007;146:1232-1244.
156. Falenski KW, et al. Temporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus. Brain Res 2009;1262:64-72.
157. Bhaskaran MD, Smith BN. Cannabinoid-mediated inhibition of recurrent excitatory circuitry in the dentate gyrus in a mouse model of temporal lobe epilepsy. PLoS One 2010;5:e10683.
158. Sayers KW, et al. Statistical parametric mapping reveals regional alterations in cannabinoid CB1 receptor distribution and G-protein activation in the 3D reconstructed epileptic rat brain. Epilepsia 2012;53:897-907.
159. Ludanyi A, et al. Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J Neurosci 2008;28:2976-2990.
160. Romigi A, et al. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia 2010;51:768-772.
161. Wyeth MS, et al. Selective reduction of cholecystokinin-positive basket cell innervation in a model of temporal lobe epilepsy. J Neurosci 2010;30:8993-9006.
162. Sun C, et al. Loss of cholecystokinin-containing terminals in temporal lobe epilepsy. Neurobiol Dis 2014;62:44-55.
163. Karlocai MR, et al. Redistribution of CB1 cannabinoid receptors in the acute and chronic phases of pilocarpine-induced epilepsy. PLoS One 2011;6:e27196.
164. Magloczky Z, et al. Dynamic changes of CB1-receptor expression in hippocampi of epileptic mice and humans. Epilepsia 2010;51(Suppl. 3):115-120.
165. Chen K, et al. Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron 2003;39:599-611.
166. Chen K, et al. Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures. J Neurosci 2007;27: 46-58.
167. Hill AJ, Hill TD, Whalley B. The development of cannabinoid based therapies for epilepsy. In: Murillo-Rodriguez (Ed.) Endocannabinoids: molecular, pharmacological, behavioral and clinical features. bentham science publishers, Oak Park, IL, 2013, pp 164-204.
168. Manna SS, Umathe SN. Involvement of transient receptor potential vanilloid type 1 channels in the pro-convulsant effect of anandamide in pentylenetetrazole-induced seizures. Epilepsy Res 2012;100:113-124.
169. Luszczki JJ, et al. Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol 2006;547:65-74.
170. Luszczki JJ, et al. Effect of arachidonyl-2'-chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the protective action of the various antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:18-25.
171. Luszczki JJ, et al. Synthetic cannabinoid WIN 55,212-2 mesylate enhances the protective action of four classical antiepileptic drugs against maximal electroshock-induced seizures in mice. Pharmacol Biochem Behav 2011;98:261-267.
172. Luszczki JJ, et al. Effects of WIN 55,212-2 mesylate (a synthetic cannabinoid) on the protective action of clonazepam, ethosuximide, phenobarbital and valproate against pentylenetetrazole-induced clonic seizures in mice. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1870-1876.
173. Andres-Mach M, et al. Effect of ACEA--a selective cannabinoid CB1 receptor agonist on the protective action of different antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model. Prog Neuropsychopharmacol Biol Psychiatry 2012;39: 301-309.
174. Luszczki JJ, et al. Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice. Eur J Pharmacol 2013;720:247-254.
175. Florek-Luszczki M, et al. Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB 2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model. J Neural Transm 2014;121: 707-715.
176. Florek-Luszczki M, Zagaja M, Luszczki JJ. Influence of WIN 55,212-2 on the anticonvulsant and acute neurotoxic potential of clobazam and lacosamide in the maximal electroshock-induced seizure model and chimney test in mice. Epilepsy Res 2014;108:1728-1733.
177. Florek-Luszczki M, et al. Effects of WIN 55,212-2 (a synthetic cannabinoid CB1 and CB2 receptor agonist) on the anticonvulsant activity of various novel antiepileptic drugs against 6Hz-induced psychomotor seizures in mice. Pharmacol Biochem Behav 2015; 130:53-58.
178. Chesher GB, Jackson DM. The effect of withdrawal from cannabis on pentylenetetrazol convulsive threshold in mice. Psychopharmacologia 1974;40: 129-135.
179. Chesher GB, Jackson DM, Malor RM. Interaction of delta9-tetrahydrocannabinol and cannabidiol with phenobarbitone in protecting mice from electrically induced convulsions. J Pharm Pharmacol 1975;27:608-609.
180. National Toxicology Program. NTP toxicology and carcinogenesis studies of 1-trans-delta(9)-tetrahydrocannabinol (CAS No. 1972-08-3) in F344 rats and B6C3F1 mice (gavage studies). Natl Toxicol Program Tech Rep Ser 1996;446:1-317.
181. Hill AJ, et al. Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol 2012;167:1629-1642.
182. Oviedo A, Glowa J, Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 1993;616:293-302.
183. Rodriguez de Fonseca F, et al. Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 1994;47:33-40.
184. Sim LJ, et al. Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 1996;16:8057-8066.
185. Fan F, et al. Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain Res 1996;706:13-20.
186. Romero J, et al. Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res 1997;46:100-108.
187. Romero J, et al. Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTP gamma S binding in morphine-dependent mice. Drug Alcohol Depend 1998;50:241-249.
188. Romero J, et al. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol. J Mol Neurosci 1998;11:109-119.
189. Romero J, et al. Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. Synapse 1998;30:298-308.
190. Zhuang S, et al. Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Brain Res Mol Brain Res 1998;62:141-149.
191. Hsieh C, et al. Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem 1999;73:493-501.
192. Corchero J, et al. Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudateputamen. Brain Res Mol Brain Res 1999;67:148-157.
193. Breivogel CS, et al. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 1999;73:2447-2459.
194. Breivogel CS, et al. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur J Pharmacol 2003;459:139-150.
195. McKinney DL, et al. Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 2008;324:664-673.
196. Sim-Selley LJ, Martin BR. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxaz inyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther 2002;303:36-44.
197. Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 2003;15:91-119.
198. Sim-Selley LJ, et al. Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration. Mol Pharmacol 2006;70:986-996.
199. Martin BR, Sim-Selley LJ, Selley DE. Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol Sci 2004;25:325-330.
200. Villares J. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 2007;145:323-334.
201. Coutts AA, et al. Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci 2001;21:2425-2433.
202. Lundberg DJ, Daniel AR, Thayer SA. Delta(9)-Tetrahydrocannabinol-induced desensitization of cannabinoid-mediated inhibition of synaptic transmission between hippocampal neurons in culture. Neuropharmacology 2005;49:1170-1177.
203. Deshpande LS, Blair RE, DeLorenzo RJ. Prolonged cannabinoid exposure alters GABA(A) receptor mediated synaptic function in cultured hippocampal neurons. Exp Neurol 2011;229:264-273.
204. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986;38:151-178.
205. Abood ME, et al. Development of behavioral tolerance to delta 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol Biochem Behav 1993;46:575-579.
206. Ten Ham M, Loskota WJ, Lomax P. Acute and chronic effects of beta9-tetrahydrocannabinol on seizures in the gerbil. Eur J Pharmacol 1975;31:148-152.
207. Corcoran ME, McCaughran JA, Jr., Wada JA, Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled rats. Epilepsia 1978;19: 47-55.
208. Colasanti BK, Lindamood C, 3rd, Craig CR. Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats. Pharmacol Biochem Behav 1982;16: 573-578.
209. Karler R, Turkanis SA. Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice. Br J Pharmacol 1980;68:479-484.
210. Blair RE, et al. Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy. Neuropharmacology 2009;57:208-218.
211. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci 1976;282:221-239.
212. Jones RT, Benowitz NL, Herning RI. Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 1981;21(8-9 Suppl.):143S-152S.
213. Kirk JM, de Wit H. Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacol Biochem Behav 1999;63:137-142.
214. Hart CL, et al. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl) 2002;164:407-415.
215. Babor TF, et al. Marijuana consumption and tolerance to physiological and subjective effects. Arch Gen Psychiatry 1975;32:1548-1552.
216. Nowlan R, Cohen S. Tolerance to marijuana: heart rate and subjective "high". Clin Pharmacol Ther 1977;22:550-556.
217. Aceto MD, et al. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol 1995;282:R1-R2.
218. Tsou K, Patrick SL, Walker JM. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 1995;280:R13-R15.
219. Rodriguez de Fonseca F, et al. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997;276:2050-2054.
220. Kaymakcalan S. Tolerance to and dependence on cannabis. Bull Narc 1973;25:39–47.
221. Beardsley PM, Balster RL, Harris LS. Dependence on tetrahydrocannabinol in rhesus monkeys. J Pharmacol Exp Ther 1986;239:311-319.
222. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006;19:233-238.
223. Karler R, et al. Interaction between delta-9-tetrahydrocannabinol and kindling by electrical and chemical stimuli in mice. Neuropharmacology 1984;23:1315-1320.
224. Karler R, Calder LD, Turkanis SA. Prolonged CNS hyperexcitability in mice after a single exposure to delta-9-tetrahydrocannabinol. Neuropharmacology 1986;25:441-446.
225. Hegde M, et al. Seizure exacerbation in two patients with focal epilepsy following marijuana cessation. Epilepsy Behav 2012;25:563-566.
226. Ellison JM, Gelwan E, Ogletree J. Complex partial seizure symptoms affected by marijuana abuse. J Clin Psychiatry 1990;51:439-440.
227. Leite JR, Carlini EA. Failure to obtain "cannabis-directed behavior" and abstinence syndrome in rats chronically treated with cannabis sativa extracts. Psychopharmacologia 1974;36:133-145.
228. Robson P. Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 2011;10:675-685.
229. Wade DT, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-441.
230. Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers 2007; 4:1729-1743.
231. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007;29: 2068-2079.
232. Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 2006;42:495-503.
233. Crippa JA, et al. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther 2013;38:162-164.
234. Allsop DJ, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry 2014;71:281-291.
235. Allsop DJ, Lintzeris N, Copeland J, Dunlop A, McGregor IS. Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal. Clin Pharmacol Ther 2015;97:571-574.
236. Keeler MH, Reifler CB. Grand mal convulsions subsequent to marijuana use. Case report. Dis Nerv Syst 1967;28:474-475.
237. Lapoint J, et al. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila) 2011;49:760-764.
238. Jinwala FN, Gupta M. Synthetic cannabis and respiratory depression. J Child Adolesc Psychopharmacol 2012;22:459-462.
239. Hermanns-Clausen M, et al. Acute intoxication by synthetic cannabinoids—four case reports. Drug Test Anal 2013;5:790-794.
240. Hermanns-Clausen M, et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013;108: 534-544.
241. McQuade D, et al. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol 2013; 69:373-376.
242. Pant S, et al. Spicy seizure. Am J Med Sci 2012;344:67-68.
243. Tofighi B, Lee JD. Internet highs—seizures after consumption of synthetic cannabinoids purchased online. J Addict Med 2012;6:240-241.
244. de Havenon A, et al. The secret "spice": an undetectable toxic cause of seizure. Neurohospitalist 2011;1:182-186.
245. Castaneto MS, et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014;144:12-41.
246. Davis JP, Ramsey HH. Anti-epileptic action of marijuana-active substances. Fed Proc Am Soc Exp Biol 1949;8:284.
247. Consroe PF, Wood GC, Buchsbaum H. Anticonvulsant nature of marihuana smoking. JAMA 1975;234:306-307.
248. Lorenz R. On the application of cannabis in paediatrics and epileptology. Neuro Endocrinol Lett 2004;25:40-44.
249. Mortati K, Dworetzky B, Devinsky O. Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature. Rev Neurol Dis 2007;4:103-106.
250. Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001;42:1266-1272.
251. Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia 2014;55: 783-786.
252. Corral VJ. Differential effects of medical marijuana based on strain and route of administration: a three-year observational study. J Cannabis Ther 2001;1:43-59.
253. Hamerle M, et al. Cannabis and other illicit drug use in epilepsy patients. Eur J Neurol, 2014;21:167-170.
254. Gieringer D. Madical use of cannabis: experience in California. Haworth Press, Binghamton, NY, 2001.
255. Feeney D, Spiker M. Marijuana and epilepsy: activation of symptoms by delta-9-THC. In: C.S and S.RC (Eds.). The therapeutic potential of marihuana. Plenum Press, New York, 1976.
256. Alldredge BK, Lowenstein DH, Simon RP. Seizures associated with recreational drug abuse. Neurology 1989;39:1037-1039.
257. Brust JC, et al. Marijuana use and the risk of new onset seizures. Trans Am Clin Climatol Assoc 1992;103:176-181.
258. Gross DW, et al. Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center. Neurology 2004;62:2095-2097.
259. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 2013;29:574-577.
260. Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav 2015;45: 49–52.
261. Mechoulam R, Carlini EA. Toward drugs derived from cannabis. Naturwissenschaften 1978;65:174-179.
262. Cunha JM, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21:175-185.
263. Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J 1986; 69:14.
264. Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. In: Marijuana '90 international conference on cannabis and cannabinoids, Kolympari, Crete, 1990.
265. van Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat 2008;4:1001-1019.
266. Dravet C. The core Dravet syndrome phenotype. Epilepsia 2011;52(Suppl. 2):3-9.
267. Mathern GW, Beninsig L, Nehlig A. Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: result of Epilepsia's survey. Epilepsia 2015;56:1-6.
268. Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med 2014;371:879.
269. Morales-Munoz I, et al. Characterizing cannabis-induced psychosis: a study with prepulse inhibition of the startle reflex. Psychiatry Res 2014;220:535-540.
270. Lynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: a review. Addiction 2000;95:1621-1630.
271. Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 2011;5: 1-8.
272. Lisdahl KM, et al. Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry 2013;4:53.
273. Crane NA, Schuster RM, Gonzalez R. Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users. J Int Neuropsychol Soc 2013;19:1009-1015.
274. Jacobus J, et al. Cortical thickness and neurocognition in adolescent marijuana and alcohol users following 28 days of monitored abstinence. J Stud Alcohol Drugs 2014; 75:729-743.
275. Gilman JM, et al. Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. J Neurosci 2014;34: 5529-5538.
276. Gruber SA, et al. Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity. Psychopharmacology (Berl) 2014;231:1455-1465.
277. Tortoriello G, et al. Miswiring the brain: Delta9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO J 2014;33:668-685.
278. Raver SM, Haughwout SP, Keller A. Adolescent cannabinoid exposure permanently suppresses cortical oscillations in adult mice. Neuropsychopharmacology 2013;38:2338-2347.
279. Raver SM, Keller A. Permanent suppression of cortical oscillations in mice after adolescent exposure to cannabinoids: receptor mechanisms. Neuropharmacology 2014;86:161-173.
280. Houck JM, Bryan AD, Feldstein Ewing SW. Functional connectivity and cannabis use in high-risk adolescents. Am J Drug Alcohol Abuse 2013;39:414-423.
281. Pavisian B, et al. Effects of cannabis on cognition in patients with MS: a psychometric and MRI study. Neurology 2014;82:1879-1887.
282. Guy GW, Robson PJ. A phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis based medicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers (GWPK0112). J Cannabis Ther 2003;3:79-120.
283. Hawksworth G, McArdle K. Metabolism and pharmacokinetics of cannabinoids. Pharmaceutical Press, London, 2004.
284. Bornheim LM, et al. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol 1993;45:1323-1331.
285. Yamaori S, et al. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 2011;39:2049-2056.
286. Jiang R, et al. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 2011;89:165-170.
287. Yamaori S, et al. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 2011;88:730-736.
288. Jiang R, et al. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet 2013;28:332-338.
289. Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev 2014;46:86-95.
290. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2: 473-481.
291. Yamaori S, et al. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 2010;79:1691-1698.
292. Friedman D, et al. The effect of Epidiolex (Cannabidiol) on serum levels of concomminant anti-epileptic drugs in children and young adults with treatment-resistant epilepsy in an expanded access program. In: American Epilepsy Society, Seattle, WA, 2014.
293. Espay AJ, et al. Placebo effect of medication cost in Parkinson disease: a randomized double-blind study. Neurology 2015;84:794-802.
294. Weimer K, et al. Placebo effects in children: a review. Pediatr Res 2013;74:96-102.
295. Kemeny ME, et al. Placebo response in asthma: a robust and objective phenomenon. J Allergy Clin Immunol 2007;119:1375-1381.
296. Rheims S, et al. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med 2008;5: e166.
297. Anon. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut Syndrome. The Group for the Evaluation of Cinromide in the Lennox-Gastaut Syndrome. Epilepsia 1989;30:422-429.
298. Rekand T. THC:CBD spray and MS spasticity symptoms: data from latest studies. Eur Neurol 2014;71(Suppl. 1):4-9.
299. Naderi N, et al. Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. J Neural Transm 2008;115:1501-1511.
300. Naderi N, et al. Modulation of anticonvulsant effects of cannabinoid compounds by GABA-A receptor agonist in acute pentylenetetrazole model of seizure in rat. Neurochem Res 2011;36:1520-1525.
301. Vilela LR, et al. Effects of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole-induced seizure and electroencephalographic activity in rats. Epilepsy Res 2013;104:195-202.
302. Shubina L, Aliev R, Kitchigina V. Attenuation of kainic acid-induced status epilepticus by inhibition of endocannabinoid transport and degradation in guinea pigs. Epilepsy Res 2015;111:33-44.
303. Wendt H, et al. Targeting the endocannabinoid system in the amygdala kindling model of temporal lobe epilepsy in mice. Epilepsia 2011;52:e62-e65.
304. Wallace MJ, et al. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 2001;428:51-57.
305. Payandemehr B, et al. Involvement of PPAR receptors in the anticonvulsant effects of a cannabinoid agonist, WIN 55,212-2. Prog Neuropsychopharmacol Biol Psychiatry 2015;57:140-145.
306. van Rijn CM, et al. WAG/Rij rats show a reduced expression of CB(1) receptors in thalamic nuclei and respond to the CB(1) receptor agonist, R(+)WIN55,212-2, with a reduced incidence of spike-wave discharges. Epilepsia 2010;51:1511-1521.
307. Citraro R, et al. CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations. Epilepsy Res 2013; 106:74-82.
308. Lambert DM, et al. Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 2001;42:321-327.
309. Sheerin AH, et al. Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid. Epilepsia 2004;45:1184-1188.
310. Wallace MJ, Martin BR, DeLorenzo RJ. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 2002;452:295-301.
311. Shafaroodi H, et al. The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice. Neuropharmacology 2004;47:390-400.
312. Bahremand A, et al. The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is potentiated by ultra-low dose naltrexone in mice. Epilepsy Res 2008;81:44-51.
313. Bahremand A, et al. Involvement of nitrergic system in the anticonvulsant effect of the cannabinoid CB(1) agonist ACEA in the pentylenetetrazole-induced seizure in mice. Epilepsy Res 2009;84:110-119.
314. Rudenko V, et al. Inverse relationship of cannabimimetic (R+)WIN 55, 212 on behavior and seizure threshold during the juvenile period. Pharmacol Biochem Behav 2012;100:474-484.
315. Di Maio R, Cannon JR, Timothy Greenamyre J. Post-status epilepticus treatment with the cannabinoid agonist WIN 55,212-2 prevents chronic epileptic hippocampal damage in rats. Neurobiol Dis 2014;73C:356-365.
316. Rizzo V, et al. Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat. Neurosci Lett 2009;462:135-139.
317. Kow RL, et al. Modulation of pilocarpine-induced seizures by cannabinoid receptor 1. PLoS One 2014;9:e95922.
318. Kozan R, Ayyildiz M, Agar E. The effects of intracerebroventricular AM-251, a CB1-receptor antagonist, and ACEA, a CB1-receptor agonist, on penicillin-induced epileptiform activity in rats. Epilepsia 2009;50:1760-1767.
319. Cakil D, et al. The effect of co-administration of the NMDA blocker with agonist and antagonist of CB1-receptor on penicillin-induced epileptiform activity in rats. Epilepsy Res 2011;93:128-137.
320. van Rijn CM, et al. Endocannabinoid system protects against cryptogenic seizures. Pharmacol Rep 2011;63:165-168.
321. Vinogradova LV, Shatskova AB, van Rijn CM. Pro-epileptic effects of the cannabinoid receptor antagonist SR141716 in a model of audiogenic epilepsy. Epilepsy Res 2011;96:250-256.
322. Gholizadeh S, et al. Ultra-low dose cannabinoid antagonist AM251 enhances cannabinoid anticonvulsant effects in the pentylenetetrazole-induced seizure in mice. Neuropharmacology 2007;53:763-770.
323. Dudek FE, et al. The effect of the cannabinoid-receptor antagonist, SR141716, on the early stage of kainate-induced epileptogenesis in the adult rat. Epilepsia 2010;51(Suppl. 3):126-130.
324. Echegoyen J, et al. Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model. Epilepsy Res 2009;85:123-127.
325. Sofia RD, Kubena RK, Barry, H, 3rd. Comparison among four vehicles and four routes for administering delta9-tetrahydrocannabinol. J Pharm Sci 1974;63:939-941.
326. Chesher GB, Jackson DM. Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacologia 1974;37:255-264.
327. Johnson DD, et al. Epileptiform seizures in domestic fowl. V. The anticonvulsant activity of delta9-tetrahydrocannabinol. Can J Physiol Pharmacol 1975;53:1007-1013.
328. Wada JA, Osawa T, Corcoran ME. Effects of tetrahydrocannabinols on kindled amygdaloid seizures and photogenic seizures in Senegalese baboons, Papio papio. Epilepsia 1975;16:439-448.
329. Boggan WO, Steele RA, Freedman DX. 9 -Tetrahydrocannabinol effect on audiogenic seizure susceptibility. Psychopharmacologia 1973;29:101-106.
330. Corcoran ME, McCaughran JA, Jr., Wada JA. Acute antiepileptic effects of 9-tetrahydrocannabinol in rats with kindled seizures. Exp Neurol 1973;40:471-483.
331. Wada JA, et al. Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled cats. Epilepsia 1975;16:503-510.
332. Turkanis SA, et al. An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats. Epilepsia 1979;20:351-363.
333. Izquierdo I, Orsingher OA, Berardi AC. Effect of cannabidiol and of other cannabis sativa compounds on hippocampal seizure discharges. Psychopharmacologia 1973;28:95-102.
334. Karler R, Turkanis SA. Cannabis and epilepsy. Adv Biosci 1978;22-23:619-641.
335. Consroe P, et al. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 1982;83:293-298.
336. Shirazi-zand Z, et al. The role of potassium BK channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal electroshock models of seizure in mice. Epilepsy Behav 2013;28:1-7.
337. Hill TD, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol 2013;170:679-692.
338. Jones NA, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 2012;21:344-352.